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Abstract
Introduction: More than 70 common alleles are known to be involved in breast cancer (BQ susceptibility, and
several exhibit significant heterogeneity in their associations with different BC subtypes. Although there are
differences in the association patterns between BRCA1 and BRCA2 mutation carriers and the general population for
several oei, no study has comprehensively evaluated the assodations of all known BC susceptibility alleles with risk
of BC subtypes in BRÜ\1 and BRCA2 carriers.
Methods: We used data from 15,252 BRO\1 and 8,211 BRCA2 carriers to analyze the associations between
approximately 200,000 genetic variants on the iCOGS array and risk of BC subtypes defined by estrogen receptor
(ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and triple-negative- CTN) status;
morphologic subtypes; histological grade; and nodal involvement.
Results:The stimated BC hazard ratios (HRs) forthe 74 known BC alleles in BRCA1 carriers exhibited moderate
correlations with the corresponding odds ratios from the general population. However, their associations with
ER-positive BC in BRCA1 carriers were more consistent with the ER-positive associations in the general population
(intradass correlation (ICC) = 0.61,95% confidence interval (Cl): 0.45 to 0.74), and the same was true when considering
ER-negative associations in both groups (ICC = 0.59, 95% Cl: 0.42 to 0.72). Similarly, there was strong correlation between
the ER-positive associations for BROM and BRCA2 carriers (ICC = 0.67, 95% Cl: 0.52 to 0.78), whereas ER-positive
assodations in any one of the groups were generally inconsistent with ER-negative assodations in any of the others.
After stratifying by ER status in mutation carriers, additional significant associations were observed. Several previously
unreported variants exhibited associations at P <10-6 in the analyses by PR status, HER2 status, TN phenotype,
morphologic subtypes, histological grade and nodal involvement.
Conclusions: Differences in assodations ofcommon BC susceptibility alleles between BRCA1 and BRCA2 carriers and
the general population are explained to a large extent by differences in the prevalence ofER-positive and ER-negative
tumors. Estimates of the risks assodated with these variants based on population-based studies are likely to be
applicable to mutation carriers after taking ER status into account, which has implications for risk prediction.
Introduction
Women who carry pathogenic mutations in BRCA1 or
BRCA2 have markedly increased risks of developing
breast cancer. The distributions of breast cancer tumor
characteristics differ between BRCA1 mutation carriers,
BRCA2 mutaüon carriers and those arising in the gen-
eral population. The majority of breast umors arising in
BRCA1 carriers show low or absent expression of estro-
gen receptor (ER) [1-3], whereas the majority OÏBRCA2-
associated tumors are ER-positive [1,4,5].
Many common breast cancer susceptibility alleles iden-
tified through populaüon-based genome-wide assodation
studies (GWASs) have also been associated with breast
cancer risk in BRCA1 and BRCA2 carriers [6,7]. Several of
these variants are specificaüy associated with the ER status
of the breast cancer in the general population [8,9].
Among the single-nucleotide polymorphisms (SNPs) that
have been evaluated in mutation carriers so far, the
variants found to be associated with breast cancer isk for
BRCA1 carriers largely overlap with loei for which stron-
gei associations with ER-negative breast cancer have been
reported in the general population [8-12]. An important
quesdon for risk modelling and prevention studies is
whether the effects of common variants on breast cancer
risk in mutaüon carriers are mediated through a generic
influence on the development of pardciilar hormone re-
ceptor subtypes of breast cancer or through epistatic inter-
action with the BRCA1/2 mutation itsetf.
Previous studies by the Consortium of Investigators of
Modifiers of BRCA1/2 (CIMBA) described the impact
of 29 breast cancer susceptibility variants from non-
hereditary breast cancer studies on ER-positive and ER-
negative breast cancer risk in BRCA1 and BRCA2
carriers [6,7,13-15]. These analyses demonstrated that,
despite the lack of an association between some suscep-
tibüity variants and overall breast cancer risk for BRCA1
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or BRCA2 carriers, residual associations exist with spe-
cific disease subtypes. In addition, the ER-specific asso-
ciations in BRCA1 and BRCA2 carriers were mainly in
the same direction and of a magnitude similar to the as-
sociations observed with breast cancer stratified by ER
expression status in the general population. However,
these studies were conducted on smaller numbers of
mutation carriers than currenüy avaüable and evaluated
only a subset of the currently known breast cancer sus-
ceptibüity alleles for their associations with ER-specific
subtypes in carriers. Recently, 45 additional SNPs have
been found to be associated with breast cancer risk in
the general population [8-10,16]. Eighteen of these SNPs
showed evidence of association with ER-positive breast
cancer, bat not with ER-negative breast cancer, and four
loei (lq32.1 LGR6, 2p24.1, 16ql2 and 20qll) were asso-
ciated only with ER-negative breast cancer in the gen-
eral population. These 45 newly discovered loei have
not yet been evaluated for their associations with breast
cancer risk for mutation carriers.
In the present study, we assessed the disease subtype-
specific associations of all 74 previously reported breast
cancer susceptibility variants in 15,252 BRCA1 and
8,211 BRCA2 carriers. We evaluated whether differences
in associations of known breast cancer susceptibüity var-
iants between BRCA1 carriers, BRCA2 carriers and the
general population are mediated by tumor ER status in
mutation carriers. We also analyzed the associaüons of
about 200,000 variants on the iCOGS genotyping array
with subtype-specific breast cancer isk in carriers in an
attempt to uncover previously unreported subtype-
specific associations in women with BRCA1 and BRCA2
mutations. In addition to ER and progesterone receptor
(PR) status, we report, for the first time to our know-
ledge, assodations by HER2 status and with triple-
negative disease (TN, referring to ER-, PR- and human
epidermal growth factor receptor 2 (HER2)-negative),
and we also describe associations with clinical features
such as "ductal, no specified subtype" (hereafter referred
to as ductal) and lobular morphologic subtypes, nodal
status and histological grade.
Methods
Study subjects
Data were obtained from 47 studies in 27 different coun-
tries in CIMBA [17]. Eligible study subjects were women
who carry pathogenic mutations in BRCA1 01 BRCA2.
The majority were recruited through cancer genetics
clinics and enrolled into national or regional studies.
Written informeel consent was obtained from au sub-
jects. Each of the host insütutions recruited under ethic-
ally approved protocols. A list of the local institutional
review boards that provided ethical approval for this
study is given in Additional file l: Table SI. Eligibüity
was restricted to mutation carriers who were 18 years
of age or older at recruitment. Data collected included
year of birth, age at cancer diagnosis, personal history
of bilateral prophylactic mastectomy and/or bilateral
salpingo-oophorectomy, mutation description, tumor
pathology and ethnicity.
Tumor pathology data
Breast tumor pathology data were gathered from a range
of sources, specifically patiënt pathology reports, path-
ology review data, tumor registry records and tissue
microarray results. These included information on ER,
PR and HER2 status; morphologic subtype; lymph node
involvement; and histological grade. For ER, PR and
HER2, status was classified as negativo or posiüve, with
supplementary immunohistochemisfay scoring or bio-
chemical data and methodology provided when avaüable.
The vast majority of centers employed a cutoff of either
210% or S l % of tumor nuclei staining positive to define
ER and PR positivity. Additional file l: Table S2 lists the
subtype definitions used by each study, which were not
centrally reclassified, owing to the low proportion of re-
cords with supporting staining data. Similarly, HER2 sta-
tus was determined using immunohistochemistry to
detect streng complete membrane staüüng (with a score
of 3+ considered positive) and/or in situ hybridization to
detect HER2 gene amplification. To ensure consistency
across studies, when information on the cells stained
was avaüable, we used the same cutoff to define ER-,
PR- and HER2-positive tumors. The cutoffs used for the
small number of cases where composite scoring methods
based on the proportion and intensity of staining were
avaüable (Allred score, immunoreactive Remmele score)
are given in Additional file l: Table S2. Consistency
checks were performed to validate receptor data against
supplementary scoring information, if provided. Each
cancer was assigned to a morphologic subgroup (ductal,
lobular, medullary, other), which we confirmed using the
Wbrld Health Organization International CIassification
of Diseases for Oncology (ICD-0) code for the classifi-
caüon of tumor type when sufficient mformation was
provided [18]. Lymph node status, along with the num-
ber of nodes showing metastatic carcinoma, was pro-
vided when available. Histologic grade was assigned as
grade l, 2 or 3 by local pathologists who used a modified
Scarff-Bloom-Richardson malignancy grading system,
Genotyping and quality control
Genotyping was carried out using the iCOGS custom
array. The array development and detaüs of the genotyp-
ing and quality control for the CIMBA samples are de-
scribed in detaü elsewhere [6,7]. Briefly, genotyping for
BRCA2 carriers was conducted at McGill University and
Genome Québec Innovation Centre (Canada) and for
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BRCA1 carriers at the Mayo Clinic (USA). SNPs were
excluded if they were located on the Y chromosome, if
they were monomorphic, if they deviated significantly
from Hardy-Weinberg equilibrium (P <10 ) or if they
had call rates <95%. Samples were excluded if they had a
call rate <95%, if they were of non-European ancestry or
if they demonstrated extreme heterozygosity. After qual-
ity control, we had 200,720 SNPs avaüable for analysis in
15,252 BRCA1 samples and 200,908 SNPs avaüable for
analysis in 8,211 BRCA2 samples.
Statistical methods
We evaluated the associaüons of each genotype with risks
of developmg breast cancer or breast cancer subtypes de-
fined by the tumor characteristics or morphology. The
analyses were carried out within a survival analysis frame-
work. Individuals were censored at the first of the fol-
lowing events: breast cancer diagnosis, ovarian cancer
diagnosis, büateral mastectomy or age at last follow-up. In
order to account for non-random ascertamment of muta-
tion carriers with respect o their disease phenotype, we
used a retrospective likelihood approach that models the
probability of observing the genotypes conditional on the
disease phenotype [19,20]. It was assumed that he cancer
inddence depends on the underlying SNP genotype
through a Cox proportional hazards model:
Ai(fi)=Ao(fi)exp(pz;),
where Xo(t;) is the baseline incidence and p is the loga-
rithm of the per-allele hazard ratio (HR, under a multi-
plicative model). The association with overall breast
cancer risk was evaluated by testing the hypothesis that
P = O [20].
We evaluated the associations with the groups of each
subtype class (for example, ER-positive and ER-negative),
usmg an extension of the retrospecüve likelihood ap-
proach to model the simultaneous efGect of each SNP on
more than one tumor subtype [15]. Briefly, dus involves
modeling the conditional likelihood of the observed SNP
genotypes and tumor subtypes, given the disease pheno-
types. Wiüun this framework, it is possible to estimate
simultaneously the HRs for each tumor subtype and test
for heterogeneity in the associations [15]. To maximize
the avaüable information, genotyped mutation carriers
that were missing information on tumor characteristics
were included in the analysis, and their disease subtype
was assumed to be missing at random. In order to account
for non-mdependence among relaüves, a robust variance
estimation approach was used [20]. Further detaüs of the
methods for evaluating the associations with overall breast
cancer [20] and tumor subtypes have been described else-
where [15]. We carried out association analyses by subtype
for the foUowmg breast cancer characteristics: ER-positive
and ER-negative, PR-positive and PR-negative, HER2-
positive and HER2-negative, TN breast cancer (that is,
negative for ER, PR and HER2) and non-TN (that is,
tumor positive for at least one of the three receptors),
ductal morphologic subtype, lobular morphologic subtype,
nodal involvement (no involved lymph nodes and at least
one involved lymph node) and histological grade (high
grade (grade 3) and non-high grade (grades l and 2)).
Only samples with complete mformaüon on ER, PR and
HER2 expression were included in the analysis for TN as
well as non-TN breast cancer. The SNP associations by
tumor morphologic subtype were evaluated by comparing
ductal tumors to all others and, in a separate analysis,
lobular tumors to all others. We are not repordng associ-
ation analyses for risk of medullary morphologic subtype,
owing to sparse data as well as the difficulties in diagnos-
ing medullary breast umors reliably [21,22]. All analyses
were sü-atified by country of residence. The United States
and Canada strata were fürther subdivided by reported
Ashkenazi Jewish ancesüy. For subtypes with small
groups, strata of geographicaUy close countries were com-
bined to provide suf&cientiy large groups for estimation,
All analyses used calendar year- and cohort-specific an-
eer incidences for BRCA1 and BRCA2. SNPs with minor
allele frequencies <3% were excluded. The retrospective
likelihood was modeled using custom-written füncüoiis im-
plemented in the pedigree analysis ofitware MENDEL [23].
When evaluatmg whether the known breast cancer
susceptibüity loei identified through population based
studies also modify breast cancer risk in mutation car-
riers, a significance threshold of P <0.05 was used be-
cause of the streng prior evidence of association for
these loei with disease risk. For the association analyses
of all the approxünately 200,000 variants on the iCOGS
array with the breast cancer subtypes in mutation car-
riers, only associations with P < 5 x 10 were considered
significant. The discussion of findings and the tables
were extended to associations at P <10-6.
For variants associated with ER-positive or ER-negadve
breast cancer with P <0.01, we evaluated whether the asso-
ciations may have been affected by a possible survival bias
due to mclusion of prevalent breast cancer cases in the
analysis. For the sensitivity analysis, the association ana-
lysis by ER status was repeated after excluding mutation
carriers diagnosed with breast cancer s5 years prior to
study recruitment
We evaluated the consistency between the breast can-
eer assodation estimates of previously reported breast
cancer susceptibüity variants in the general population
(using published data) and the association estimates in
BRCA1 and BRCA2 carriers using the intraclass correl-
ation (ICC). We estimated ICC as outlined by Shrout and
Fleiss [24] based on a one-way random-effects model and
tested for agreement in absolute values of log HR. The
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same approach was used to evaluate the agreement be-
tween associaüons with ER-positive and/or -negative
breast cancer in the general population and assodations
with ER-positive and/or -negative breast cancer in BRCA1
and in BRCA2 carriers. Furthermore, we carried out the
same comparisons between associations for BRCA1 and
associations for BRCA2 carriers.
Results
Subtype patterns
The analyses induded data from 15,252 BRCA1 carriers
and 8,211 BRCA2 carriers. Among the breast cancer-
affected BRCA1 carriers, we had data on at least one
disease characteristic of interest for 4,619 (59%) of the
7,797 affected women (Table l). Data were avaüable on
tumor characteristics for 2,570 (59%) of the 4,330 af-
fected BRCA2 carriers. Of the individuals with path-
ology information, 74% of the BRCA1 carriers and 75%
of the BRCA2 carriers had data on ER status.
Single-nucleotide polymorphism associations
After quality control, genotype data were available for
analysis for 200,720 SNPs for BKCA1 carriers and for
200,908 SNPs for BRCA2 carriers. After adjusting for
sample size and excluding SNPs chosen for inclusion on
the genotyping array based on reported associations in
subsets of the current sample, the inflaüon coefBcient
^iooo values were 1.01 for ER-positive disease in BRCA1
carriers, 1.02 for ER-negative in BRCA1, 1.01 for ER-
positive in BRCA2 and 1.02 for ER-negaüve in BRCA2
carriers (Additional file l: Figure SI and Figure S2).
Similar patterns were observed for other tumor charac-
teristics (results not shown). After excluding variants lo-
cated at known breast cancer susceptibüity loei, there
was no evidence for an excess in associations by ER sta-
tus beyond the number expected.
Associations of previously reported breast cancer
susceptibility loei
Associations with overall breast cancer and by tumor
estrogen receptor status
Fkst, we considered the associations with risk for overall
breast cancer and for tumor subtypes for the 74 breast
cancer susceptibüity variants that have been reported up
to Aprü 2013. In light of the strong prior evidence of
association, we considered associations at P <0.05 as
Table 1 Breast tumor characteristics of 7,797 affected BRCA1 mutation carriers and 4,330 affected BRCA2 mutation
carriers'
BRCA1 mutation carriers BRCA2 mutation carriers
Yes, n (%) No, n (%) Unknown status Yes, n (%) No, n (%) Unknown status
Predictive markers
ER-positive
PR-positive
HER2-positive
Non-TN
Morphology
Ductal
Lobular
Medullary
Other
Grade
Grade 1
Grade 2
Grade 3
Nodal involvement
Stage
Stage Ob
Stage 1
Stage 2
Stage 3
Stage 4
819(24)
662 (21)
182 (9)
580(31)
3,159(82)
89(2)
290 (6)
470(10)
81 (3)
574(18)
2,497 (79)
1,103 (33)
65(4)
825 (46)
772 (43)
127(7)
17(1)
2,639 (76)
2,485 (79)
1,816(91)
1,310(69)
4,339
4,650
5799
5907
3,789
2,274 (67)
4,645
4,420
5,991
1,490 (77)
1,099(65)
121 (13)
760 (85)
1,770 (79)
188 (8)
39(2)
246(11)
113(7)
700 (42)
839 (51)
804 (43)
121 (13)
327 (35)
390(41)
96(10)
14(1)
434 (23)
591 (35)
847 (87)
136(15)
2,406
2,640
3,362
3,434
2,087
1,068 (57)
3,840
2,458
3,382
'ER, Estrogen receptor positive; HER2, Human epidermal growth factor eceptor 2; PR, Progesterone receptor; TN, Triple-negative. "Cardnoma in situ.
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evidence that a previously reported breast cancer sus-
cepübility aUele also modifies overall or ER-specific
breast cancer risk in mutation carriers. The associations
with overall breast cancer risk and risk of breast cancer
subtypes for all 74 variants are given in Table 2 and
Addiüonal Gie l: Tables S4 to S10. Of the breast cancer
susceptibility loei that had not previously been evaluated
for an association in mutation carriers, SNPs at 5q33.3,
8q24.21, llq24.3, 12q22, 16ql2.1, 22ql3.1 were associ-
ated with overall breast cancer risk for BRCA1 carriers,
and SNPs at 6p23, llq24.3 and 16ql2.1 were associated
with breast cancer risk for BRCA2 carriers at P <0.05
(Table 2). Overall, 15 breast cancer susceptibility variants
were associated with ER-negaüve breast cancer in BRCA1
carriers and 8 variants in BRCA2 carriers at P <0.05
(Table 2). Ten significant assodations with ER-positive
breast cancer in BRCA1 carriers and fourteen 'm BRCA2
carriers were found. The strongest association with ER-
positive breast cancer was observed for rs2981579 in
FGFR2 at 10q26.12 for both BRCA1 and 5I?CA2 carriers.
SNP rsl0069690 in TERT at 5p 15.33 displayed the stron-
gest association with ER-negative breast cancer for BRCA1
carriers and rs9348512 at 6p24.3 for BRCA2 carriers. We
found significant differences in the associations by ER sta-
tus for rs3803662 in TOX3 at 16ql2.1 (P=2x 10-4) and
rsl3387042 at 2q35 (P =0.002) for BRCA1 carriers, which
were not previously seen. Both SNPs showed evidence of
association with ER-positive breast cancer only. Similarly,
six of the loei that did not show evidence of association
with overaü breast cancer were associated with ER-
positive and two with ER-negative breast cancer in BRCA1
carriers. This included two of the loei not previously eval-
uated in mutation carriers: 3q26.1 and 6p25.3. In BRCA2
carriers, four of the variants lacking evidence of associ-
ation with overaü breast cancer were associated with ER-
negative and three with ER-positive breast cancer. This
included four loei not previously evaluated in mutation
carriers: 2q24, 14ql3.3, 19ql3.31 and 22ql2.2. Of the
breast cancer susceptibility loei that had not yet been eval-
uated for an association with breast cancer in mutation
carriers, rsl011970 at CDKN2A/B and rsl292011 at
12q24.21 had sigruficandy different associaüons with ER-
positive and ER-negative cancer for BRCA1 carriers (Phet =
0.009 and Phet = 0.004, respecüvely, for the difference be-
tween ER-posiüve and ER-negative). SNP rs2236007 at
14ql3.3 displayed differences by ER status for BRCA2 car-
riers (Phei = 0.008). These three SNPs had associations in
different direcüons for ER-positive and ER-negative
tumors.
When association analyses for ER-positive and -negaüve
disease were repeated after excluding prevalent breast
cancer cases (Addiüonal file l: Table S3), the HR estünates
were consistent with the estimates from the complete
sample but were associated with larger confidence
intervals. Therefore, it is unlikely that our results are influ-
enced by survival bias.
Associations with other subtypes and clinical features
The pattern of associations of previously reported breast
cancer susceptibüity variants by PR and TN status were
very simüar to that by ER status (Additional file l:
Tables S4 and S6), bat fewer assodations were observed
at P <0.01. SNP rs720475 at 7q35 was the only variant
that was associated with HER2-positive disease (HR=
1.45 and .P =0.003 for HER2-positive, Phet=9xl0-4 in
BRCA2 carriers) (Additional ffle l: Table S5).
For BRCA1 carriers, there were significant differences
(.Phet <0.01) in the HR for high grade (grade 3) and
grades l and 2 breast cancer for SNPs at 10q26.12
(FGFR2) and at 12q24.21 (Additional ffle l: Table S9).
SNP rs3803662 in TOX3 at 16ql2.1 was associated ex-
clusively with node-positive breast cancer (P = 2 x 10-4,
Phet = 0.005) (Additional ffle l: Table S10). This was also
the only variant associated with lobular cancer, as shown
in Additional fde l: Table S8 (P=8xl0-6 for BRCA2
carriers). The HR for lobular cancer was larger than that
for non-lobular cancer (lobular HR = 1.57, 95% Cl: 1.29
to 1.92; non-lobular HR = 1.20, 95% Cl: 1.13 to 1.28 for
BRCA2 carriers; .Phet = 9 x 10 ). There was no evidence
for differences in associations by histological grade and
nodal involvement for BRCA2 carriers.
Comparison of patterns of associatlons by breast cancer
estrogen receptor status between BRCA 1 and BRCA2
carriers and the genera/ population
We compared the log HR estimates for the breast cancer
association of known breast cancer susceptibüity variants
for BRCA1 carriers, BRCA2 carriers, and for the general
poptdaüon using published data from the Breast Cancer
Association Consortium (BCAC) [8], The resulting ICC
coef&cients for log HR/OR estimates for all comparisons
are shown in Table 3. Log HR esümates for overall
breast cancer risk in BRCA2 carriers were very similar to
the log odds ratios (ORs) from the general population
(ICC=0.63, 95% Cl: 0.47 to 0.75) (Additional me l:
Figure S3B), whereas there was only moderate correl-
ation between the log HR estimates for BRCA1 carriers
and the log HR estimates from both other groups (ICC:
BRCA1-KCAC estimates = 0.43, BRCA1-BRCA2 = 0.46)
(Addiüonal file l: Figure S3A,C). When comparing ER-
positive specific associations, we found stronger agree-
ment between the log HR/OR esümates than for overall
breast cancer. The ICC esümates ranged from 0.61 (95%
Cl: 0.45 to 0.74) (Figure 1B) for KCAC-BRCA1 to 0.69
(95% Cl: 0.55 to 0.79) (Figure IC) for KCAC-BRCA2.
The ER-negative breast cancer log HR estimates in
BRCA1 carriers and the corresponding BCAC estimates
were strongly correlated (ICC=0.59, 95% Cl: 0.42 to
Table 2 Assodations of susceptibility loei with^yerall and estrogen receptor-positive and -negative breast cancer"
BRCA1 carriers
Locus SNP Positionb Nearby
gene
Ref- W K' MAF
Overall
HR (95% Cl) P-value
ER-negative
HR (95% Cl) P-value
ER-positive
HR (95% Cl) P-value Phrt-value
f
l
1 p36.22
1p13.2
1p11.2
1q32.1a
1q32.1b
2p24.1
2q 14.2
2q31.1
2q31.1
2q35
2q35
3p26.1
3p24.1
3p24.1
4q24
4q34.1
5p15.33
5p15.33
5p15.33
5p12
5q11.2
5q11.3
5q11.3
Sq33.3
6p25.3
6p24.3
6p23
6q14
6q25.1
6q25.1
rs61 &488
rs12022378
rs11249433
rs66789M
rs4245739
rs12710696
rs4849887
rs2016394
rsl550623
rs13387042
rs16857609
rs6762644
rs4973768
rs12493607
rs9790S17
rs6828523
rs10069690
rs7725218
rs2736108
rs10941679
rs889312
rs 10472076
rs 1353747
rs1432679
rs11242675
rs9348512
rs204247
rs17530068
rs3757318
rs2046210
10566215
114448389
121280613
202187176
204518842
19320803
121245122
172972971
174212894
217905832
218296508
4742276
27416013
30682939
106084778
175846426
1279790
1282414
1297488
44706498
56031884
58184061
58337481
158244083
1318878
10456706
13722523
82193109
151914113
151948366
PEX14
SYT6
FCGRIB
LGR6
MDM4
OSR1
DLX2
CDOV
mp;
DIRC3
ITPR1
5LC4A7
TGFBR2
TET2
EBF1
TERT
TERT
TERT
MRP530
MAP3K1
RAB3C
PDE4D
FOXQ1
TFAP2A
RANBP9
FAM46A
ESRV
ESR1
A
G
A
G
A
G
G
G
A
A
G
A
G
c
G
c
G
G
G
A
A
A
A
A
A
c
A
A
G
G
(j
A
G
A
c
A
A
A
G
G
A
G
A
G
A
A
A
A
A
G
c
G
c
G
G
A
G
G
A
A
No
No
Yes
No
Yes
No
No
No
No
Yes
No
No
Yes
No
No
No
Yes
Yes
Yes
Yes
Yes
No
No
No
No
Yes
No
Yes
Yes
Yes
0.32
0.16
0.41
0.4
0.28
0.39
0. 11
0.47
0.15
0.47
0.26
0.36
0.49
0.35
0.23
0.11
0.28
0.36
0.29
0,25
0.29
0.37
0.09
0.44
0.35
0.34
0.44
0.25
0.08
0.37
0.96 (0.92 to 1.01)
1.03 (0.98 to 1.09)
0.99 (0.95 to 1.04)
0.98 (0.94 to 1.02)
1.10 (1.05 to 1.15)
1.01 (0.97 t0 1.06)
1.02 (0.96 to 1.09)
1.01 (0.97 to 1.06)
1.01 (0.95 to 1.07)
0.98 (0.94 to 1.02)
1.04 (1.00 to 1.09)
1.04 (0.99 to 1.08)
1.01 (0.97 to 1.06)
0.99 (0.95 to 1.04)
0.98 f0.94to1.03)
1.03 (0.96 to 1.1)
1.21 (1.15to1.26)
1.08 (1.04 to 1.13)
0.89 (0.85 to 0.93)
0.99 (0.94 to 1.04)
1.01 (0.97 to 1.06)
1.00 (0.96 to 1.05)
0.98 (0.91 to 1.05)
1.05 (1.00 to 1.09)
0.96 (0.92 to 1)
1.00 (0.95 to 1.04)
1.00(0.96(0 1.04)
1.03(0.98to1.08)
1.20(1.11 tot.29)
1.16 (1.12 to 1.21)
0.10
0.25
0.78
0.39
4.6 X (T5
0.51
0.53
0.54
0.72
0.41
0.06
0.09
0.47
0.73
0.51
0.41
l.lxio-15
3.2 xl O-4
4.2x1 (T7
0.61
0.52
0.83
0.53
0.03
0.06
0.87
0.98
0.23
1.1 x10-6
2.4x10-12
0.95 (0.90 to 1.00)
1.03 (0.97 to 1.10)
0.99 (0.94 to 1.03)
0.96 (0.91 t0 1.01)
1.12 (1.07 to 1.19)
1.01 (0.97 to 1.07)
1.01 (0.94 to 1.09)
1.03 (0.98 to 1.08)
1.02 (0.95 to 1.09)
1.02 (0.97 to 1.07)
1.03 (0.98 to 1.09)
1.00 (0.95 to 1.05)
0.99 (0.95 to 1.04)
0.99(0.9410 1.04)
0.97 (0.92 to 1.03)
1.03 (0.95 to 1.11)
1.24 (1.18 to 1.31)
1.09(1.04 to 1.15)
0.86 (0.82 to 0.91)
0.99 (0.94 to 1.05)
0.99 (0.94 to 1.05)
0.98 (0.94 to 1.03)
0.95 (0.88 to 1.04)
1.03 (0.98 to 1.08)
0.94 (0.90 to 0.99)
1.00 (0.95 to 1.05)
1.00 (0.95 to 1.04)
1.03 (0.97 to 1.09)
1.24(1.14101.35)
1.20 (1.15 to 1.26)
0.07
0.31
0.55
0.08
1.4XKT5
0.57
0.78
0.23
0.54
0.37
0.23
0.92
0.81
0.63
0.30
0.47
2.7 x KT15
6.4 Xl O"4
1.1XKT7
0.84
0.82
0.52
0.28
0.25
0.03
0.88
0.84
0.29
5.6x10-7
2.8XKT13
1.00 (0.90to1.10)
1.03 (0.90 to 1.17)
1.02 (0.93 to 1.13)
1.06 (0.97 tol.17)
1.02(0.91 to 1.13)
1.01 (0.92 to 1.12)
l.05(0.90 to 1.23)
0.96 (0.87 to 1.06)
0.97 (0.85 tol.12)
0.86 (0.78 to 0.95)
1.08 (0.97 to 1.21)
1.16d.05to1.28)
1.09 (0.99 to 1. 19)
1.01 (0.92 to 1.11)
1.03 (0.92to1.15)
1.02 (0.88 to 1.19)
1.09 (0.98 to 1.22)
1.05 (0.95 to 1.15)
0.98 (0.88 to 1.08)
0.97 (0.86 to 1.08)
1.09(0.98(0 1.21)
1.08(0.9810 1.18)
1.06 (0.90 to 1.24)
1.10(1.01 to 1.21)
1.01 (0.91 to 1.11)
1.00(0.90(01.10)
1.01 (0.92 to 1.12)
1.03 (0.92 to 1.14)
1.06 (0.89 to 1.26)
1.04 (0.94 to 1.15)
0.92
0.68
0.63
0.21
0.76
0.77
0.49
0.39
0.72
1.9 XlO-3
0.14
2.9x10-3
0.07
0.85
0.61
0.78
0.09
0.37
0.68
0.54
0.12
0. 13
0.50
0.04
0.90
0.95
0.75
0.63
0.51
0.42
0.47
0.94
0.50
0.07
0.11
1.00
0.64
0.21
0.57
2.3x10-3
0.47
0.01
0.10
0.70
0.37
0.94
0.04
0.47
0.04
0.66
0.15
0.11
0.29
0.21
0.28
1.00
0.72
0.95
0.12
0.01
o
^
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s
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Table 2
7q35
8p12
8q21.11
8q21.11
8q24.21
8q24.21
9p21.3
9q31.2
9q31.2
10p12.31
10p12.31
10q21.2
10q22.3
10q25.2
10q26.12
10q26.12
11p15.5
11q13.1
11q13.3
11q13.3
1q13.3
1q24.3
12p13.1
12p11.22
12q22
12q24.21
13q13.1
14q 13.3
14q24.1
14q24.1
14q32.11
16q12.1a
16q12.1b
Associations
rs720475
of susceptibility loei with overall and estrogen receptor-positive and -negative breast cancer" (Continued)
!
s"
s
0^
co
i
rs9693444
rs6472903
rs2943559
rs11780156
rs13281615
rs1011970
rs10759243
rs865686
rs7072776
rs11814448
rs10995190
rs704010
rs7904519
rs2981579
rs11199914
rs3817198
rs3903072
rs5S4219
d 1_pos690
88342
rs494406
rs 11820646
rs12422552
rs10771399
rsl7356907
rs1292011
rs11571833
rs2236007
FS2588809
rs999737
rs941764
rs3803662
rs11075995
144074929 ARHGEF5
29509616 DU5P4
76230301
76417937 HNF4G
129194641 MYC
128355618
22062134 CDKN2B
110306115 KLF4
110888478 KLF4
22032942 MLLT10
22315843 DNAIC1
64278682 ZNF365
80841148 ZMIZ1
114773927 TCF7U
123337335 FGFR2
123093901 FGFR2
1909006
65583066
69331642
69379161
69344241
129461171
14413931
28155080
96027759
115836522
32972626
37132769
68660428
69034682
91841069
52586341
53855291
LSP1
SNX32
CCND1
BARX2
ATF71P
PTHLH
NTN4
TBX3
BRCA2
PAX9
RAD51L 1
CCDCS8C
TOX3
/TO
ü A Yes
C A Yes
A C Yes
A G Yes
G A No
A G Yes
C A Yes
C A No
A C Yes
G A No
A C No
G A Yes
G A Yes
A G Yes
G A Yes
G A No
A G Yes
C A No
C G Yes
C A Yes
G
G
G
A
A
A
T
G
G
G
A
G
A
A
A
c
G
G
G
A
A
A
A
G
A
T
Yes
No
No
Yes
No
Yes
No
No
No
Yes
No
Yes
No
0.26
0.33
0.17
0.08
0.19
0.43
0.17
0.31
0.36
0.31
0.02
0.15
0.37
0.47
0.42
0.33
0.33
0.47
0.12
0.06
0.25
0.39
0.27
0.10
0.29
0.41
0.01
0.21
0.19
0.21
0.34
0.29
0.24
0.98 (0.93 to 1.03)
1.01 (0.96 t0 1.05)
1.01 (0.96 t0 1.07)
1.06 (0.98 to 1.14)
0.95 (0.9 to 1)
1.02 (0.98 to 1.06)
1.02 (0.97 to 1.08)
0.98(0.94to1.02)
0.99 (0.95 to 1.04)
0.99 (0.94 to 1.03)
0.99 (0.93 to 1.05)
1.01 (0.97 to 1.06)
1.09 (1.05 to 1.14)
0.99 (0.95 to 1.04)
1.02 (0.98 to 1.07)
1.08 (1.03 to 1.13)
0.99 (0.95 to 1.03)
1.03 (0.97 to 1.09)
1.03 (0.95 to 1.13)
1.02 (0.97 to 1.07)
0.93 (0.89 to 0.97)
1.01 (0.97 to 1.06)
0.85 (0.80 to 0.91)
0.95(0.91 to 1.00)
1.00 (0.96 to 1.05)
1.02 (0.83 to 1.26)
0.97 (0.92 to 1.02)
0.96(0.91 to 1.01)
0.96(0.91 to 1.01)
1.03 (0.98 to 1.07)
1.06(1.01 to 1.11)
1.01 (0.96 to 1.06)
0.36
0.80
0.74
0.12
0.05
0.44
0.47
0.39
0.77
0.52
0.70
0.48
1.6 x10-5
0.81
0.27
6.5x10-4
0.69
0.37
0.45
0.46
5.9x10-4
0.63
1.9x1(T6
0.03
0.82
0.83
0.19
0.09
0.09
0.23
0.02
0.61
0.98 (0.93 to 1.04)
1.01 (0.96 to 1.06)
1.01 (0.95 to 1.08)
1.07 (0.98 TO 1.17)
0.96 (0.90 to 1.02)
1.01 (0.96 t0 1.06)
1.07(1.00 to 1.14)
0.98 (0.93 to 1.03)
1.02 (0.97 to 1.07)
0.96(0.91 to 1.01)
1.10 (0.94 to 1.29)
1.02 (0.96to1.09)
0.99(0.9410 1.04)
1.09 (1.04 to 1.14)
0.92 (0,8710 0.96)
1.04 (0.99 to 1.10)
1.08 (1.03 to 1.14)
1.00 (0.95 to 1.05)
1.00 (0.93 to 1.08)
1.00 (0.90 to 1.12)
1.02 (0.97 to 1.08)
0.94 (0.90 to 0.99)
1.01 (0.96 to 1.07)
0.83 (0.77 to 0.9)
0.94 (0.90 to 1.00)
1.04 (0.99 to 1.10)
1.05 (0.83to1.34)
0.95 (0.90 to 1.01)
0.95 (0.89 to 1.01)
0.98 (0.92 to 1.04)
1.02 (0.97 to 1.07)
1.01 (0.96 to 1.07)
0.98 (0.93 to 1.04)
0.54
0.69
0.77
0.12
0.15
0.73
0.05
0.49
0.52
0.11
0.22
0.49
0.61
6.4 xl O-4
6.9x1(T4
0.09
2.9x1 (T3
0.94
0.96
0.95
0.42
0.03
0.68
1.2 X KT5
0.03
0.08
0.66
0.13
0.13
0.43
0.47
0.65
0.60
0.96 (0.86 to 1.08)
0.99 (0.90 to 1.09)
1.01 (0.89 tol.14)
1.02(0.86101.22)
0.93 (0.82 to 1.05)
1.04 (0.95 to 1.15)
0.87 (0.76 to 0.99)
0.98 (0.88 to 1.08)
0.92 (0.83 to 1.02)
1.08 (0.98 to 1.20)
1.25 (0.93 to 1.69)
0.88 (0.76 tol.00)
1.12(1.01 to 1.23)
1.12d.02to1.23)
1.29 (1.17 to 1.43)
0.96 (0.86 to 1.06)
1.07 (0.97 to 1.18)
0.96 (0.87 to 1.05)
1.12 (0.97 to 1.29)
1.14 (0.93 to 1.39)
1.00 (0.90 tol.12)
0.88 (0.79 to 0.97)
1.01 (0.91 to 1.13)
0.91 (0.78 to 1.06)
0.98 (0.88 to 1.09)
0.88 (0.80 to 0.97)
0.92 (0.53 to 1.59)
1.01 (0.90 to 1.14)
0.97 (0.86 to 1.09)
0.90 (0.80 to 1.01)
1.05 (0.95 tol.17)
1.22 (1.10 to 1.35)
1.1 (0.99 to 1.24)
0.53
0.83
0.89
0.78
0.23
0.38
0.04
0.64
0.11
0.12
0.15
0.06
0.03
0.02
3.1 Xl O-7
0.43
0.17
0.39
0.12
0.20
0.97
8.9x10-3
0.85
0.24
0.71
0.01
0.75
0.87
0.56
0.07
0.34
1.5X10-4
0.07
0.79
0.72
0.99
0.68
0.70
0.55
9.3x1 (T3
0.93
0.10
0.04
0.50
0.05
0.03
0.59
7.5x10-"
0.17
0.89
0.44
0.20
0.30
0.74
0.20
0.99
0.36
0.56
4.39 x10~"3
0.66
0.42
0.85
0.22
0.62
2.39x10-3
0.07
s
Table 2 Assodations of susceptibility loei with overall and estrogen receptor-positive and -negative breast cancer" (Continued)
16q12.1b rs17817449 53813367 FTO AC
16q23.2 rs13329835 80650805 CDYU A G
17q22 rs6504950 53056471 COX11 G A
18q11.2 rs527616 24337424 AQP4 C G
18q11.2 rs 1436904 22824665 A C
19p13.11 rs8170 17389704 BABAM1 G A
19p13.11 rs4808801 18571141 ELL A G
19q13.31 rs3760982 44286513 KCNN4 G A
21q21.1 rs2823093 16520832 NRIP1 G A
22q12.2 rs132390 29621477 EMID1 A G
22q13.1 rs6001930 40876234 SGSM3 A G
No 0.41 0.95 (0.91 to 0.99) 0.02
No 0.23 1.04 (0.99 to 1.09) 0.09
Yes 0.27 0.98 (0.94 to 1.03) 0.49
No 0.37 0.99 (0.95 t0 1.03) 0.61
No 0.39 0.99 (0.95 to 1.03) 0.68
Yes 0.19 1.19 (1.12 to 1.25) 2.9x10-
No 0.32 0.98 (0.94 to 1.02) 0.40
No 0.46 1.03 (0.9910 1.08) 0.10
Yes 0.27 0.95 (0.91 to 1) 0.04
No 0.03 0.98 (0.87 to 1.1) 0.75
No 0.11 1.07 (1.00 to 1.14) 0.03
0.94 (0.89 to 0.98) 9.8x10~3 1.00 (0.91 to 1.10) 0.99 0.26
l.03 (0.97 to 1.09) 0.29 1.08 (0.97 to 1.21) 0.17 0.48
0.99 (0.94 to 1.04) 0.70 0.96 (0.87 to 1.07) 0.49 0.68
0.97 (0.93 to 1.02) 0.30 1.04 (0.94 to 1.15) 0.42 0.26
1.00 (0.95 to 1 .05) 0.86 0.98 (0.89 to 1.08) 0.63 0.74
1.22 (1.15 to 1.30) 1.7 x 10-1° 1 .06 (0.95 to 1.20) 0.30 0.05
0.99 (0.94 to 1.05) 0.81 0.94 (0.85 to 1.04) 0.23 0.35
1.03 (0.98 to 1.08) 0.19 1.04 (0.95 to 1.14) 0.41 0.90
0.96 (0.91 to 1.02) 0.17 0.92 (0.82 to 1.02) 0.11 0.44
0.93(0.81 to 1.07) 0.30 1.16 (0.91 to 1.46) 0.23 0.13
1.06 (0.98 to 1.15) 0.14 1.11 (0.96 to 1.30) 0.17 0.60
l
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Table 2 Associations of susceptibility loei with overall and estrogen receptor-positive and -negativo breast cancer"
BRCA2 carriers
Locus SNP Position1 Nearby
gene
Ref Effd K° MAF
Overall
HR (95% Cl) P-value
ER-negative
HR (95% Cl) P-value
ER-positive
HR (95% Cl) P-value Phei-value'
l
%
a
l
g
P'
s
1p36.22
1p13.2
1p11.2
1q32.1a
1q32.1b
2p24.1
2q 14.2
2q31.1
2q31.1
2q35
2q35
3p26.1
3p24.1
3p24.1
4q24
4q34.1
Spi 5.33
Spi 5.33
5p15.33
5p12
5q11.2
5q11.3
5q11.3
5q33.3
6p25.3
6p24.3
6p23
6q14
6q25.1
6q25.1
rs616488
rsl2022378
rs11249433
rs6678914
rs4245739
rs12710696
rs4849887
rs2016394
rs1550623
rs13387042
rs16857609
rs6762644
rs4973768
rs12493607
rs9790517
rs6828523
is10069690
IS7725218
rs2736108
rs10941679
rs889312
rs10472076
rs1353747
rs1432679
rs11242675
rs9348512
FS204247
rs17530068
rs3757318
rs2046210
10566215
114448389
121280613
202187176
204518842
19320803
121245122
172972971
174212894
217905832
218296508
4742276
27416013
30682939
106084778
175846426
1279790
1282414
1297488
44706498
56031884
58184061
58337481
158244083
1318878
10456706
13722523
82193109
151914113
151948366
PEX14
SYT6
FCGR1B
LGR6
MDM4
05fl;
DLX2
CDC47
TNP1
DIRC3
ITPR1
5LC4A7
TOFBR2
TB-2
EBF1
TERT
TERT
TERT
MRPS30
MAP3K1
RAB3C
PDE4D
FOXQ1
TFAP2A
RANBP9
FAM46A
E5R1
ESR1
G
A
G
A
c
A
A
A
G
G
A
G
A
G
A
A
A
A
A
G
c
G
c
G
G
A
G
G
A
A
No
No
Yes
No
Yes
No
No
No
No
Yes
No
No
Yes
No
No
No
Yes
Yes
Yes
Yes
Yes
No
No
No
No
Yes
No
Yes
Yes
Yes
0.33
0.17
0.41
0.41
0.28
0.38
0.11
0.46
0.15
0.48
0.27
0.37
0.5
0.34
0.22
0.1
0.27
0.36
0.3
0.24
0.3
038
0.09
0.45
0.36
0.34
0.44
0.25
0.09
0.37
0.98(0.9210 1.04)
1.03(0.95(01.12)
1.05 (0.99 to 1.12)
1.04 t0.98to1.10)
0.97(0.91 to 1.04)
1.00 (0.94 to 1.06)
0.98 (0.89 to 1.08)
0.99 f0.93to1.05)
0.97 (0.89 to 1.06)
0.99(0.9310 1.05)
0.96(0.90(0 1.03)
0.98 f0.93to1.05)
1.08 (1.02 to 1.15)
0.98 (0.92 to 1.04)
0.97(0.91 tol.05)
0.98 (0.89 tol.08)
1.11 (1.04 to 1.19)
1.06 (0.99 to 1.12)
0.93(0.88 to 1.00)
1.07 (1.00 to 1.15)
1.04 t0.98to1.11)
0.99 (0.93 to 1.05)
0.95 (0.86 to 1.05)
1.01 (0.95 to 1.07)
1.01 (0.95 to 1.07)
0.85 (0.8 to 0.9)
1.09 (1.03 to 1.15)
1.10 (1.03 to 1.18)
1.15d.03to1.28)
1.06 (0.99 to 1.12)
0.52
0.42
0.09
0.19
0.38
0.99
0.72
0.74
0.49
0.68
0.26
0.61
7.8x1 (T3
0.54
0.48
0.72
1.6x10-3
0.08
0.04
0.03
0.21
0.78
0.35
0.79
0.79
9.2x10-8
3.4x1 (T3
7.2x10-3
0,01
0.07
1.01 (0.88 to 1.16)
1.16 (0.97 to 1.37)
1.04(0.91 to 1.19)
0.94 (0.82 to 1.08)
1.09 (0.95 to 1.26)
1.14(1.00to1.30)
1.08(0.87to1.33)
l.07 (0.94 to 1.22)
1.03(0.87101.23)
0.98 (0.87 to 1.12)
0.87 (0.74 to 1.01)
1.08(0.94to1.24)
1.05 (0.92 to 1.20)
1.07 f0.93to1.22)
0.91 (0.77 to 1.07)
1.05 (0.85 to 1.30)
1.25 (1.08 to 1.44)
1.07 (0.93 to 1.23)
0.91 (0.78 to 1.05)
1.09 (0.94 to 1.27)
0.99 (0.86 to 1.14)
1.02(0.89(01.17)
1.02(0.81 to 1.27)
0.92(0.81 to 1.04)
1.02(0.89101.18)
0.79 (0.69 to 0.91)
1.08 (0.94 to 1.24)
1.07 (0.92 to 1.25)
1.33(1.07to 1.65)
1.15d.00to1.33)
0.94
0.10
0.57
0.39
0.21
0.05
0.49
0.32
0.70
0.82
0.08
0.27
0.46
0.35
0.25
0.64
3.2 xl (T3
0.35
0.20
0.24
0.90
0.78
0.88
0.16
0.75
1.1x1(T3
0.25
0.40
9.1x10-3
0.04
0.97 (0.9 to 1.05)
1.00(0.91 to 1.1)
1.06 (0.99 to 1.13)
1.07(1.00 to 1.15)
0.94 (0.87 to 1.01)
0.96 (0.9 to 1.03)
0.96 (0.85 to 1.07)
0.97 (0.9 to 1.04)
0.95 (0.87 to 1.05)
0.99 (0.93 to 1.06)
0.99 (0.92 to 1.07)
0.96(0.89to 1.03)
1.10 (1.02 to 1.18)
0.96 (0.89 to 1.03)
0.99(0.91 to 1.08)
0.96 (0.86 to 1.08)
1.08(1.0010 1.17)
1.05 (0.98 to 1.13)
0.94 (0.87 to 1.02)
1.07(0.99(0 1.15)
1.06(0.98(0 1.14)
0.98 (0.92 to 1.05)
0.94 (0.83 to 1.05)
1.04 (0.97 to 1.11)
l.00 (0.93 to 1.08)
0.86 (0.8 to 0.92)
1.09(1.02 to 1.17)
1.11 (1.02 to 1.2)
1.09 (0.96 to 1.24)
1.03 (0.96 to 1.1)
0.46
1.00
0.12
0.05
0.10
0.28
0.43
0.36
0.31
0.74
0.82
0.24
0.01
0.23
0.88
0.51
0.06
0.17
0.13
0.09
0. 14
0.64
0.26
0.30
0.90
3.4X10"5
9.7x10-3
0.01
0.17
0.43
0.69
0.15
0.84
0.11
0.07
0.02
0.34
0.21
0.41
0.96
0.14
0.13
0.58
0.17
0.35
0.49
0.09
0.85
0.67
0.78
0.44
0.66
0.52
0.09
0.83
0.32
0.93
0.70
0.12
0.17
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10p12.31 rs11814448
10q21.2 rs10995190
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0.09
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0.29
0.36
0.3
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0.38
0.47
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0.33
0.34
0.47
0.13
0.06
Yes 0.26
0.39
0.28
Yes 0.1
No 0.3
Yes 0.41
0.03
0.21
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Yes 0.22
No 0.34
Yes 0.29
No 0.24
0.99 (0.92 to 1.06) 0.71
0.98 (0.93 to 1.05) 0.61
0.97 (0.90 to 1.05) 0.48
1.10(1.00to1.22) 0.05
0.97 (0.90 to 1.04) 0.44
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1.00 (0.94 tot.06) 0.94
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1.01 f0.95to1.07)
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16q12.1b
16q23.2
17q22
18q11.2
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19p13.11
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21q21.1
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G
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G
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G
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No 0.37
No 0.39
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No
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No
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0.46
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0.04
0.10
0.94 (0.88 to 1.00)
1.03 (0.96 to 1.11)
1.04 (0.97 to 1.11)
0.96(0.910 1.02)
0.96 (0.9 to 1.02)
0.98 (0.91 to 1.06)
0.97(0.91 to 1.03)
1.05(0.99to1.12)
0.94 (0.88 to 1.01)
1.17 t1.00to1.37)
1.02 (0.92 to 1.12)
0.03
0.35
0.24
0.19
0.14
0.62
0.33
0.09
0.09
0.05
0.71
1.05(0.91 to
0.94 (0.81 to
1.08 (0.94 to
0.95 (0.83 to
1.02 (0.89 to
1.06 (0.90 to
1.07 (0.93 to
0.97 (0.86 to
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0.92 (0.61 to
0.94 (0.76 to
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1.24)
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1.11)
1.25)
1.39)
1.18)
0.49
0.43
0.27
0.41
0.79
0.51
0.33
0.69
0.36
0.70
0.61
0.91 (0.85 t0 0.97) 6.6 x 10-3 0.08
1.06 (0.98 to 1.15) 0.13 0.17
1.03 (0.95 to 1. 11) 0.46 0.54
0.96 (0.9 to 1.03) 0.30 0.82
0.94 (0.87 to 1.01) 0.07 0.30
0.96 (0.88 to 1.05) 0.37 0.33
0.94 (0.87 to 1.01) 0.10 0.11
1.08(1.01 to 1.15) 0.03 0.19
0.91 (0.84 to 0.98) 0.02 0.06
1.24(1.04101.49) 0.02 0.22
1.04 (0.93 to 1.16) 0.48 0.44
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Table 3 Comparisons between the associations of 74 breast cancer susceptibility loei in BRCA1 carriers, in BRCA2
carriers, and in population-based studies'
BRCA1 carriers BRCA2 carriers
Overall ER-positive ER-negative Overall ER-positive ER-negative
BRCA2 carriers Overall
ER-positive
ER-negative
BCAC Overall
ER-positive
ER-negative
0.46 (0.25 to 0.62)
0.67 (0.52 to 0.78) 0.13 (-0.10 to 0.35)
0.10 (-0.13 to 0.33) 0.46 (0.25 to 0.62)
0.43 (0.22 to 0.60} 0.63 (0.47 to 0.75)
0.61 (0.45 to 0.74)
0.34 (0.12to0.53)
0.16 (-0.07to0.38)
0.59 (0.42 to 0.72)
0.69 (0.55 to 0.79) 0.1 3 (-0.11 to 0.35)
0.39 (0.17 to 0.57) 0.28 (0.05 to 0.48)
'ER, Estrogen receptor. Data are intraclass correlation meffldents and 95% confldence inten/als, which descrlbe associations wlth overall breast cancer as well as
by ER status. Data are derived from published studies by the Breast Cancer Assodation Consortium (BCAO.
0.72) (Figure IE), However, the ER-negative breast cancer
log HR estimates in BRCA2 carriers were less strongly cor-
related with the corresponding estimates in BRCA1 car-
riers (ICC = 0.46. 95% Cl: 0.25 to 0.62) (Figure 1D) and in
BCAC (ICC=0.28, 95% Cl: 0.05 to 0.48) (Figure 1F).
There was no evidence that the ICC was different from O
for the comparison between ER-positive associations in
BRCA1 carriers with ER-negative associations in BRCA2
carriers and vice versa (Additional file l: Figure S4B,C).
Sünüarly, there was no significant correlation between log
OR estimates for ER-positive breast cancer in BCAC with
log HR estünates for ER-negative breast cancer in BRCA1
and BRCA2 carriers (Additional file l: Figures S5B and
S6B). There was only moderate correlation between log
OR estimates for ER-negative breast cancer in the general
population and log HR estimates for ER-positive breast
cancer in BRCA1 and BRCA2 carriers (ICC = 0.39 and
ICC=0.34, respectively) (Additional ffle l: Figures S5C
and S6C).
Associations by subtype with all single-nucleotide
polymorphisms on iCOGS
Variants in or near the known breast cancer susceptibil-
ity loei TERT, ESR1 and 19pl3.11 showed streng associ-
ations (P <1Q ) with at least one of the categories in all
subtype analyses in BRCA1 carriers. The same was true
for SNPs in FGFR2 and TOX3 m BRCA2 carriers.
Variants on the iCOGS array that exhibited associations
at P <1Q~6 with any of the breast cancer subtypes of ER-,
FR-, HER2-positive or -negative and TN breast tumors are
shown in Table 4. All the variants associated with ER-
positive or ER-negative breast cancer at P <10~6 were
located within known breast cancer suscepübüity loei.
Smular associaüons were observed with PR-positive and
PR-negative breast cancer for BRCA1 carriers. A previ-
ously unreported SNP at 2pl3.2 was associated with
HER2-positive breast cancer in BRCA1 carriers. In BRCA2
carriers, two previously unreported variants showed
evidence of associadon in the analysis by PR status.
Furthermore, SNPs at 8ql2.1 near TOX were associated
with HER2-positive cancer in BRCA2 carriers. Only SNPs
in the known breast cancer susceptibüity loei FGFR2 and
TOX3 were associated with non-TN breast cancer in
BRCA2 carriers, and none were associated with TN breast
cancerat.P<10 .
A SNP at 7q36 was associated with ductal subtype for
BRCA1 carriers (Table 5). Two loei were associated with
lobular breast cancer for BRCA2 carriers: llq23.3 and
Xpll.23.
There was one navel associaüon with high-grade tu-
mors in BRCA1 carriers (Table 6). Three previously un-
reported variants were associated with breast cancer
nodal status in BRCA1 carriers: SNPs at 4q24 in the
TET2 gene, at 5q32 in the SH3RF2 gene and at 7p22 in
an intron of NXPH1. For BRCA2 carriers, only SNPs in
FGFR2 and TOX3 exhibited associations at P <10~6 with
breast cancer nodal status or histological grade.
Discussion
This is the first comprehensive report, to our know-
ledge, of the associations of genetic variants with risk
of developing breast cancer by tumor subtypes in
BRCA1 and BRCA2 carriers. We evaluated the associa-
tions with ER, PR and HER2 status; morphologic sub-
type (ductal or lobular); histological grade; and lymph
node status.
Prior to this study, variants at five loei (5pl5.33,
6q25.1, llpl5.5, 12pll.22 and 16ql2.1) had been shown
to be associated with breast cancer risk for both BRCA1
and BRCA2 carriers; variants at four additional oei were
known to be associated with breast cancer risk for
BRCA1 carriers only (lq32.1, 10q25.2, 14q24.1 and
19pl3.11); and variants at süc additional loei were known
to be associated with risk for BRCA2 carriers (3p24.1,
5pl2, 6p24.3, 10q26.12, llql3 and 12q24.21) [6,7,10].
Among the 43 breast cancer susceptibüity variants
that had not previously been evaluated in mutation
carriers, we observed süc assodaüons with breast cancer at
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Table 4 Associations with tumor subtypes"
Affected by subtype, n (MAF)
Subtype Sample SNP Locus Positionb Nearby Refc Effd Reportede Positive Negativo Unknown
gene
Positive
Number
unaffected
(MAF)
HR P-value
(95% Cl)
Negativo
HR P-value Phet-value'
(95% Cl)
l
%
o
ER status BRCA1 rs10069690 5p15.33 1332790 TERT G A Yes
carriers
rs2046210 6q25.1 151990059 C6orf97 G A Yes
rs2811708 9p21 21963422 CDKN2A/B C A Yes
rs45631579 10q26 123328965 FGFR2 A G Yes
rs2590275 12p12 28057334 PTHLH G C Yes
rs2363956 19p13.11 17255124 ANKLE1 C A Yes
BRCA2 rs2162540 10q26 123342126 FGFR2 A G Yes
carriers
rs17271951 16q12.1 51095541 TOX3 A G Yes
PR status BRCA1 rs10069690 5p15.33 1332790 TERT G A Yes
carriers
rs2046210 6q25.1 151990059 C6orf97 G A Yes
rs45631626 10q26 123327325 FGFR2 G A Yes
rs2590275 12p12 28057334 PTHLH G C Yes
rs8100241 19p13.1 17253894 ANKLE1 G A Yes
819
(0.27)
819
(0.36)
816
(0.24)
819
(0.48)
819
(0.26)
819
(0.47)
1450
(0.47)
1490
(0.32)
662
(0.27)
662
(0.37)
662
(0.49)
662
(0.26)
657
(0.51)
2,635
(0.3)
2,639
(0.39)
2,634
(0.31)
2,639
(0.4)
2,639
(0.25)
2,635
(0.53)
426
(0.41)
434
(0.28)
2,481
(0.29)
2,485
(0.39)
2,485
(0.4)
2,485
(0.25)
2,473
(0.47)
4,331
(0.3)
4,338
(0.38)
4,336
(0.28)
4,337
(0.42)
4,338
(0.26)
4,334
(0.52)
2,348
(0.44)
2,397
(0.3)
4,642
(0.3)
4,649
(0.38)
4,647
(0.42)
4,649
(0.26)
4,628
(0.48)
7,449
(0.26)
7,453
(0.35)
7,445
(0.28)
7,455
(0.41)
7,454
(0.28)
7,447
(0.48)
3,783
(0.38)
3,879
(0.25)
7,449
(0.26)
7,453
(0.35)
7,455
(0.42)
7,454
(0.28)
7,420
(0.52)
1.09
(0.98 to
1.22)
1.04
(0.94 to
1.15)
0.82
(0.73 to
0.91)
1.29
(1.17to
1.43)
0.92
(0.83 to
1.03)
0.98
(0.89 to
1.08)
1.34
(1.25to
1.43)
1.29
(1.2to
1.39)
1.10
(0.98 to
1.24)
1.09
(0.98 to
1.21)
1.33
(1.2to
1.48)
0.92
(0.82 to
1.03)
0.98
(0.88 to
1.09)
0.09
0.42
2.9 x10-4
2.6X10-7
0.14
0.71
3.6x1 (T16
8.4x10-'2
0.09
0.12
1.3x10-7
0.16
0.71
1.24
(1.18 to
1.31)
1.2
d.isto
1.26)
1.13
(1.07to
1. 19)
0.92
(0.87 to
0.96)
0.87
(0.82 to
0.92)
1.25
(1.19to
1.31)
1.08
(0.94 to
1.23)
1.14
(0.99 to
1.31)
1.24
(1.17t0
1.3)
1.18
(1.13to
1.24)
0.92
(0.88 to
0.97)
0.87
(0.82 to
0.92)
0.81
(0.78 to
0.85)
27x1CT15 0.04
2.8x10-13 0.01
7.3X10-6 3.9x1 (T7
4.7x10-4 5.1X1 (T9
5.3x10~7 0.34
6.4x10-20 1.6X1 (T5
0.27 6.1x1 (T3
0.08 0. 14
1.3x10-'4 0.11
2.0x1(T11 0.19
9.6x1 (T4 5.3x1 (T9
o
.
41.
A
0>
1.8x10~'7 2.4X1CT3
Table 4 Associations with tumor subtypes' (Continued)
BRCA2 rs10017576 4q28.3 139799629
carriers
G A No
FS4376461 8p12 32822117 NRG1 C A No
rs45631588 10q26 123341292 FGFR2 A G Yes
rs17271951 16q12.1 51095541 70X3 A G Yes
HER2 BRCA1 rs17008885 2p13.2 73303647 SMYD5 T A No
status carriers
rs10069690 5p15.33 1332790 TERT G A Yes
rs2046210 6q25.1 151990059 C6orf97 G A Yes
rs10843055 12p12 28063088 PTHLH A C Yes
rs4808616 19p13.11 17264033 ANKLE1 C A Yes
BRCA2 rs4305889 8q12.1 60352785 TOX A G No
carriers
rs45631588 10q26 123341292 FGFR2 A G Yes
rs3817197 11p15.5 1862750 LSP1 G A Yes
rs17271951 16q12.1 51095541 TOX3 A G Yes
1099
(0.38)
1099
(0.15)
1099
(0.47)
1099
(0.32)
182
(0.19)
181
(0.23)
182
(0.39)
171
(0.06)
176
(0.35)
121
(0.18)
121
(0.45)
121
(0.55)
121
(0.29)
591
(0.43)
591
(0.10)
591
(0-43)
591
(0.28)
1,816
(0.3)
1,813
(0.29)
1,816
(0.4)
1,743
(0.06)
1,782
(0.32)
845
(0.09)
847
(0.46)
847
(0.44)
847
(0.31)
2,639
(0.41)
2,640
(0.14)
2,640
(0.45)
2,631
(0.3)
5,799
(0.3)
5,791
(0.3)
5,798
(0.38)
5,615
(0.06)
5,706
(0.32)
3,353
(0.11)
3,362
(0.45)
3,353
(0.45)
3,353
(0.3)
3,880
(0.43)
3,881
(0.15)
3,881
(0.39)
3,879
(0.25)
7,455
(0.31)
7,449
(0,26)
7,453
(0.35)
7,234
(0.07)
7,339
(0.28)
3,874
(0.1)
3,881
(0.39)
3,877
(0.47)
3,879
(0.25)
0.83
(0.77 to
0.89)
1.00
(0.9 to
1. 12)
1.33
(1.23to
1.44)
1.32
(1.21 to
1.43)
0.54
(0.43 to
0.69)
0.9
(0.71 to
1.13)
1.12
(0.91 to
1.38)
0.79
(0.52 to
1.2)
1.37
(1.11 to
1.69)
2.04
(1.53 to
2.71)
1.27
(0.98 to
1.63)
1.30
(1.02to
1.64)
1.10
(0.85 to
1.41)
8.9X10-
0.93
2.7x10-13
4.3x10-
7.8X1CT
0.36
0.29
0.26
3.8X10-
8.7X1CT
0.07
0.03
0.47
1.02
(0.92 to
1.14)
0.6
(0.5 to
0.73)
1. 15
(1.03to
1.28)
1.14
(1.01 to
1.29)
0.99
(0.95 ta
1.04)
1.24
(1.18to
1.3)
1.17
(1.11 to
1.22)
0.79
(0.72 to
0.87)
1.2
O.Hto
1.26)
0.96
(0.85 to
1.08)
1.28
(1.19to
1.37)
0.84
(0.79 to
0.9)
1.27
(1.18t0
1.37)
0.67 2.7 Xl (T3
2.4X10-7 1.4X1CT5
0.01 0.04
0.03 0.07
0.78 3.8x10-6
3.4X10-17 0.01
1.5 Xl O-10 0.71
6.2X10-7 0.99
6.8x10-'3 0.25
0.47 1.0x10"5
2.1X10-12 0.95
9.1x10-7 1.3X1CT3
6.9X1CT" 0.3
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Table 4 Associations with tumor subtypes" (Continued)
Triple- BRCA1 rs10069690 5p15.33 1332790 IERJ
negative9 carriers
ü A Yes
rs2046210 6q25.1 151990059 C6orf97 Q A Yes
rs9512729 13q 12.2 26974865 LNX2 G A No
rs8100241 19p13.11 17253894 ANKLE1 G A Yes
BRCA2 rs2162540 10q26 123342126 FGFR2 A G Yes
carriers
rs1362548 16q12.1 51121452 TOX3 C G Yes
579
(0.27)
580
(0.37)
580
(0.34)
577
(0.5)
735
(0.46)
760
(0.32)
1,307
(0.3)
1,310
(0.41)
1,309
(0.43)
1,304
(0.46)
133
(0.36)
136
(0.29)
5,899
(0.3)
5,906
(0.38)
5,902
(0.41)
5,877
(0,48)
3,356
(0.44)
3,434
(0.31)
7,449
(0.26)
7,453
(0.35)
7,454
(0.41)
7,420
(0.52)
3,783
(0.38)
3,881
(0.26)
1.06 0.34
(0.94 to
1.19)
1.01
(0.91 to
1. 13)
0.76
(0.69 to
0.85)
0.94
(0.85 to
1.04)
1.39 9.8X10-20
(1.29to
1.49)
1.26
(1.17to
1.36)
0.79
9.1x10-
0.22
1.0x10~'
1.27 5.2x10-'4 0.02
(1.2to
1.36)
1.23 5.5x10-'2 6.8x10-3
(1.16to
1.31)
1.08 0.01 1.2x1 (T"
(1.02to
1.15)
0.81 2.4X1CT13 0.03
(0.76 to
0.86)
0.83 0.10 4.0x10-5
(0.67 to
1.03)
1.18 0.16 0.63
(0.94 to
1.49)
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lTable 5 Associations with ductal and lobular breast cancer"
N tumors with
morphology (MAF)
Other morphology Tumors with
morphology
Subtype Sample SNP Locus Position- Nearby Ref W Reported- Present Other Unknown Number HR (95% Cl) P-value HR (95% Cl) P-value P...-valuef
9ene unaflected
(MAF)
carriers
rs10069690 5p15.33 1332790 7B?7~ G A Yes
rs11155803 6q25.1 151987362 C6ort97 A G Yes
rs10252939 7q36 155587448 A G No
rs8100241 19p13.11 17253894 ANKLE1 G A Yes
BRCA2 rs2162540 10q26 123342126 FGFR2 A G Yes
carriers
rs1362548 16q12.1 51121452 TOX3 C G Yes
Lobular BRCA2 rs2186703 11q23.3 115265717 RPL15P15 A C No
carriers
rs55998524 Xp11.23 51082075 NUDT10 C G No
3,155
(0.29)
3,159
(0.36)
3,159
(0.28)
3,137
(0.48)
1,728
(0.45)
1,770
(0.3)
188
(0.07)
188
(0.11)
847 3,783
(0.30) (0.30)
848 3,786
(0.35) (0.36)
849 3,789
(0.33) (0.29)
844 3,777
(0.49) (0.47)
458 2,038
(0.44) (0.44)
473 2,087
(0.32) (0.31)
2,055 2,087
(0.03) (0.04)
2,054 2,086
(0.05) (0.06)
7,449 (0.26)
7,452 (0.32)
7,455 (0.32)
7,420 (0.52)
3,783 (0.38)
3,881 (0.26)
3,881 (0.03)
3,880 (0.05)
1.23
(1.11 to 1.36)
1.13
t1.03to1.25)
1.08
(0.98 to 1.19)
0.87
(0.79 to 0,95)
1.24
(1.08to1.42)
1.32
(1.15 to 1.51)
1.09
(0.93 to 1.27)
0.96
(0.83 to 1.1)
7.3x10-5 1.20 2.0x10-" 0.67
(1.14to 1.26)
0.01 1.17 4.6x10-"' 0.58
(1.11 to 1.23)
0.14 0.87 1.0X1CT7 2.7X10-
(0.82 to 0.91)
2.8x10-3 0.84 1.5X1 (T13 0.51
(0.8 to 0.88)
l.8x10-3 1.30 3.1X10-'4 0.55
(1.21 t0 1.39)
4.8x10-5 1.23 7.3 xl O-9 0.36
(1.15to1.32)
0.29 2.54 2.8X1CT7 1.5x10-s
(1.78to3.62)
0.54 2.42 3.6x10-8 7.0x10-°
(1.77 to 3.32)
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Table 6 Associations with grade and lymph node status"
Affected by subtype, n (MAF) Low-grade/
no nodal
involvement
High grade/
nodal
involvement
Subtype Sample SNP Locus Position" Nearby Ref Effd Reported"
gene
High- Low-
grade/ grade/
node- node-
positive negative
Unknown Number HR P-value HR P-value
unaffected (95% Cl) (95% Cl)
(MAF)
Phet-value'
i
s
GradeS BRCM rs17651413 2q33.1 202677054 KIM2012 A G No
carriers
rs10069690 5p15.33 1332790 TERT G A Yes
c6_pos1519 6q25.1 151989450 C6otf97 G A Yes
89450
rs8100241 19p13.U 17253894 ANKLE1 G A Yes
BRCA2 rs45631588 10q26 123341292 FGFR2 A G Yes
carriers
rs3585069S 16q12.1 51131844 TOX3 G A Yes
Nodes BRCAï rs1498125 4q24 106412012 TET2 A G No
carriers
rs10069690 5pl5.33 1332790 TERT G A Yes
rs 11743632 5q32 145389263 SH3RF2 G A No
rs9383936 6q25.1 151986307 C6orf97 G A Yes
2,495
(0.12)
2,493
(0.3)
2,497
(0.11)
2,483
(0.48)
839
(0.44)
839
(0.32)
1,103
(0.2)
1,100
(0.3)
1,103
(0.31)
1,103
(0.11)
655
(0.11)
654
(0.29)
655
(0.08)
653
(0.52)
813
(0.48)
813
(0.3)
2,274
(0.23)
2,271
(0.29)
2,274
(0.37)
2,274
(0.09)
4,644
(0.13)
4,638
(0.3)
4,645
(0.1)
4,622
(0.48)
2,678
(0.44)
2,678
(0.3)
4,419
(0.22)
4,414
(0.3)
4,418
(0.36)
4,420
(0.1)
7,454(0.11)
7,449 (0.26)
7,455 (0.08)
7,420 (0,52)
3,881 (0.39)
3,881 (0.26)
7,455 (0.2)
7,449 (0.26)
7,453 (0.37)
7,455 (0.08)
1.01
(0.86 to
1.2)
1.15
(1.02to
1.29)
1.01
(0.83 to
1.24)
0.95
(0.86 to
1.05)
1.36
(1.24to
1.49)
1.2
(1.09t0
1.33)
1.18
0.1 to
1.25)
1.19
(1.12to
1.26)
1.05
(0.99 to
1.11)
1.16
(1.06to
1.28)
0.86
0.02
0.91
0.36
7.4x10"
3.0x10-
4.4x10-
6.2x1 CT
0.1
1.3X1CT3
1.20
(1.12to
1.29)
1,22
(1.16to
1.29)
1.31
(1.21 to
1.42)
0.82
(0.78 to
0.86)
1.19
(1.09to
1.3)
1.31
(1.19t0
1.44)
0.98
(0.89 to
1.09)
1.24
(1.13to
1.35)
0.8
(0.74 to
0.87)
1.41
(1.24to
1.6)
8.4x10- 0.08
2.4x1 (T13 0.39
2.2X1CT" 0.02
2.2x10"16 0.01
1.7x10-4 0.06
4.0x10"
2.0x10"
0.26
0.74 5.7x10~3
0.5
2.3x1 (T7 6.9x10-
i
l
1.3x10- 0.03
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Table 6 Associations with grade and lymph node status3 (Contlnued)
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rs23494S5 7p22 8517481 NXPH1 A C No
rs11669059 l9p13.11 17261453 ANKLE1 A G Yes
BRCA2 rs2981578 10q26 123330301 FGFR2 A G Yes
carriers
rs35850695 16q12.1 51131844 TOX3 G A Yes
1,091 2,249
(0.37) (0.34)
1,103
(0.41)
795
(0.44)
804
(0.31)
2,273
(0.4)
1,047
(0.48)
1,068
(0.3)
4,374
(0.34)
4,418
(0.39)
2,428
(0.47)
2,458
(0.3)
7,398(0.37) 0.87
(0.82 to
0.92)
7,452(0.43) 0.85
(0.81 to
0.9)
3,819(0.52) 0.87
(0.8 to
0.94)
3,881 (0.26) 1.22
(1.12to
1.33)
8.5X10-/ 0.97^ 0.53 0.03
(0.90 to
1.06)
2.9x10-9 0.86 2.6x10~4 0.81
(0.80 to
0.93)
7.4x10-4 0.75 1.0X1CT9 0.02
(0.68 to
0.82)
8.5x10-" 1.30 2.6x10-7 0.36
(1.18to
1,44)
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P <0.05 in BRCA1 carriers (5p33.3, 8q24.21, llq24.3,
12q22, 16ql2.1b and 22ql3.1) and three in BRCA2 car-
riers (6p23, llq24.3 and 16ql2.1b).
After stratifying by ER status, we observed additional s-
sociations that were not seen for overall breast cancer.
Among the 43 suscepübüity variants that were evaluated
in mutation carriers for the first time, we idenüfied two
addiüonal ssociations in BRCA1 carriers when stratifying
by ER status (3q26.1, 6p25.3) and four in BRCA2 carriers
(2q24, 14ql3.3, 19ql3.3, 22ql2.2). Population-based
studies have shown that seven of the 74 breast cancer sus-
cepdbility variants display strenger associations with ER-
negaüve disease in the general popidaüon [9]. Consistent
with these findings, SNPs at lq32.1 (MDM4), 5pl5.33,
6q25.1 and 19pl3 were associated with ER-negative breast
cancer in BRCA1 carriers and SNPs at 2p24.1, 5pl5.33
and 6q25.1 in BRCA2 carriers. No data were available for
the SNP at 20qll.
We were able to confirm most of the assodations with
ER and PR subtypes of the 12 SNPs reported m the previ-
ous smaller CIMBA study [15]. In addition, two variants
from that analysis now displayed evidence at P <0.05:
rsl3387042 at 2q35 with ER-positive breast cancer in
BRCA1 carriers and rs2046210 at 6q25.1 with ER-negative
breast cancer in BRCA2 carriers.
We also evaluated the associations of the 74 previously
reported breast cancer susceptibility loei with other breast
cancer subtypes. Variants at 5pl5.33 (TERT), 6q25.1
(ESS1) and 19pl3.11 showed associadons in all subtype
analyses for BRCA1 carriers. These are the most strongly
associated loei for overall breast cancer in BRCA1 carriers,
but they had not previously been invesügated for their
roles in subtypes other than ER. Variants at these three
loei were associated with ER-, PR- and HER2-negative and
TN subtypes. These variants were also associated with risk
of high-grade tumors, with some suggestive evidence that
this association was different from the association with
grades l and 2 tumors for SNPs at ESR1 and 19pl3. The
three loei were associated with ductal as well as non-
ductal subtypes and node-positive as well as node-
negative breast cancer. For BRCA2 carriers, SNPs at loei
10q26 (FGFR2) and 16ql2.1 (TOX3) were associated with
all subtypes of breast cancer. SNPs at FGFR2 and TOX3
have consistently been associated with overall and with
ER-positive breast cancer in population-based cases [25]
as well as in BRCA1/2 carriers [15]. Furthermore, SNPs at
these two lod were associated with PR-posiüve and
HER2-negative disease. There was no evidence for a differ-
ence in HR estünates by tumor grade, nodal involvement
or morphologic subtype (ductal).
It is important to note that for each of the 74 known
loei considered, we evaluated only the associations for
the specific SNPs that have been reported by the BCAC.
We have not considered all genetic variants within a
given region. Therefore, we cannot rule out the possibü-
ity that more strongly assodated variants exist at these
loei than the SNPs reported here. Future fine-mapping
efforts in conjunction with BCAC analyses hould clarify
this. Such studies may also identify the causal variant
and together with subsequent fünctional studies gather
insights about the fünctional mechanisms causing these
associaüon signals. This in turn may yield insights about
the eüology of breast cancer in BRCA1 and BRCA2
carriers.
We compared HRs for the association with overall
breast cancer and ER-positive and ER-negative breast
cancer for all the 74 known breast cancer susceptibility
variants between BRCA1 carriers, BRCA2 carriers and
population-based studies using published data from
BCAC. Although only some of these variants were asso-
ciated at P <0.05 with breast cancer in mutation carriers
as ouüined above, diere was nevertheless strong correl-
ation between the HRs for overall breast cancer from
the general population and those from BRCA2 carriers,
and moderate correlation between the HRs from BRCA1
carriers and from BCAC. These results suggest that
many of these variants may also be associated with
breast cancer risk for mutation carriers, but the power
to detect statistically significant associations in mutation
carriers is low. These variants could be employed in risk
prediction models for mutation carriers. Future studies
should be aimed at assessing the associations of the
combined effects of the SNPs in mutation carriers in
terms of polygenic risk scores.
We used these comparisons to assess the hypothesis
that observed differences in the associations between
BRCA1 and BRCA2 carriers and the general population
are mediated by ER status. The smaller correlation be-
tween the association estimates for BRCA1 carriers and
both BCAC and BRCA2 carriers compared with those
between BCAC and BRCA2 carriers is consistent with
this hypothesis. Moreover, we found stronger correla-
tions between the HRs for ER-posiüve disease in all
three two-way comparisons (ICC=0.61 to 0.69). The
correlation between ORs for ER-negative disease from
BCAC and HRs for ER-negative disease from BRCA1
carriers was also streng (ICC=0.59). Correlaüons di-
minished when comparing HR estimates for ER-positive
with estimates for ER-negative breast cancer; most of
them were not significantly different from zero. This
finding suggests that, to a large extent, the difference in
SNP association pattems is due to mediating efifects of
tumor ER status. Under such a model, the effects of com-
mon breast cancer susceptibüity variants and of BRCA1
and BSCA2 mutaüons on breast cancer risk would be
multiplicative, after taking into account iunor ER status.
As BRCA1 carriers are more likely to develop ER-negative
disease, SNPs associated with this subtype will be more
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mformative in models to predict overall breast cancer risk
in these women, whereas SNPs associated with ER-
positive disease wiü be more usefül in BRCA2 carriers.
Furthermore, ER-specific SNP associations could be used
to provide separate estünates of ER-negative and ER-
positive breast cancer risk for mutation carriers. This un-
derstanding allows the development of more refined models
and is critical to the provision of accurate information to
women considering more targeted prevenüve options.
However, the fact that the correlations between the
HR estimates matched for ER status were smaller than l
implies that there were stilt some differences in the asso-
ciations after accounting for ER status. This could be
due to sampling error or to real differences in genetic
associations between BRCA1 and BRCA2 carriers and
the general population. There are examples for such dif-
ferences: BRCA1 and BRCA2 carrier-specific modifiers,
such as the recenüy identified variant at 6p24, which
was associated with breast cancer risk only in BRCA2
carriers [6], and the ovarian cancer susceptibiüty locus
4q32, which appeared to modify ovarian cancer risk only
for BRCA1 carriers [7]. In addition, an ovarian cancer
suscepübility locus 17qll.2 identified through population-
based data has been shown to display a consistent associ-
ation in BRCA2 carriers, whereas an association of simüar
magnitude has been ruled out in BRCA1 carriers [26]. The
extent o which geneüc susceptibility to breast cancer m
mutation carriers and in the general population is shared,
as well as the extent o which it is mediated by ER status,
need to be quantified systematically by future studies.
We also assessed the assodations of over 200,000
SNPs on the iCOGS array. We identified several variants
not previously reported that were associated with breast
cancer at P <10~6 in the analyses by PR status, HER sta-
tus, TN phenotype, histological grade, nodal involve-
ment, ductal and lobular morphologic subtypes. In the
absence of 7}-values at genome-wide significance levels
for these associations to account for multiple testing,
these associations require confirmation through by gath-
ering additional data.
Although this is the largest study of its kind, the statis-
tical power to detect associaüons of variants conferring
small efFects with specific tumor characteristics may be
low, owing to the limited data available. Future studies
of additional BRCA1 and BRCA2 carriers with detaüed
tumor pathology information on new and previously re-
cruited mutation carriers are needed. In fhis study,
tumor pathology information was retrieved primarüy
from medical records. Despite extensive efforts, it is dif-
ficult o control the quality of these data. If there is low
reproducibility inthe classification of tumor characteris-
tics for some samples, this could potentially add to the
sampling error and make it more difficult to detect
subtype-specific associations.
Conclusions
We have identified additional genetic modifiers of breast
cancer risk for mutation carriers among reported breast
cancer suscepübility loei. Large differences in absolute
risk are expected between mutation carriers who carry
many and mutation carriers who carry few risk alleles of
modifying variants [6,7]. Therefore, in combination with
previously identified modifiers, these variants may be of
value for cancer risk prediction. Moreover, our results
show that, to a large extent, the differences in breast
cancer associations of known breast cancer susceptibüity
loei between BRCA1 and BRCA2 carriers and the gen-
eral population are due to differences in the prevalence
of tumor subtypes in BRCA1 and BRCA2 carriers. Esü-
mates of the risks assodated with these genetic variants
based on large population-based association studies are
likely to be applicable also to mutation carriers after tak-
ing ER status into account. Our results thus have impli-
cations for developing risk prediction models for breast
cancer subtype-specific risks in mutation carriers that
incorporate the effects of these SNPs.
Addltional file 1: Table S1. Ethics committees that granted approval
for the access and use of the data forthls study. Table S2. Hormone
receptor definitions used by the studies. Table S3. Assodations of breast
cancer susceptibility variants with breast cancer by tumor ER status after
excluding prevalent cases. Table S4. Associations of breast cancer
susceptibility variants with breast cancer by tumor PR status. Table 55.
Associations of breast cancer susceptibility variants with breast cancer by
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Associations of breast cancer susceptibility varlants with ductal breast
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Figure 51. QQ plots tor SNP associations with ER-positive and -negative
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BRCA2 carriers. Figure S5. Comparison of the assodations ofbreast cancer
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